REFERENCES

1. Alfredo García-Arieta, et, al (2019). A Survey of the Regulatory Requirements for the Acceptance of Foreign Comparator Products by Participating Regulators and Organizations of the International Generic Drug Regulators Programme.J Pharm Pharm Sci. 2019;22(1):28-36. doi: 10.18433/jpps30215
2. Ana CerúliaMoraes do Carmo, et, al (2017). Main Reasons for Registration Application Refusal of Generic and Similar Pharmaceutical Drug Products by the Brazilian Health Regulatory Agency (ANVISA).BioMed Research International 2017(1):1-10
3. **AnupRajan, et, al (2017).** Need of Regulatory Affairs Knowledge in Pharmaceutical Industry.J PharmaPharmaSci, 2017: JPPS 114
4. B. Jayalakshmi, et, al (2019). Registration and Regulatory Requirements of Generic Drugs Marketing Authorization in "BRICS" Countries.Research J. Pharm. and Tech. 2019; 12(3): 1403-1408
5. BrahmaiahBonthagarala, (2016). Regulatory Requirements for Generic Drugs Dossier Submission in United States and Canada.International Journal of Pharmaceutical Science and Health Care Issue 6, Vol. 6 (November-December 2016)
6. B. RAMYA, et al (2017). REGULATORY REQUIREMENTS FOR MARKETING OF GENERIC DRUGS IN USA. IJPRBS, 2017; Volume 6(2): 178-195
7. B. Venkateshwarlu, et, al (2014). REGULATORY REQUIREMENTS FOR THE REGISTRATION OF GENERIC SOLID ORALS IN USA, SINGAPORE, MALAYSIA, AND THAILAND.JGTPS, 2014, Vol. 5(4): 2225 - 2232
8. ChennamsettiSrilakshmi (2017). Regulatory Requirements for Registration of API in US and EU.International Journal of PharmaAnd Chemical Research I Volume 3 I Issue 2 I Apr – Jun I 2017
9. Costas H. Kefalas, et, al (2011). The FDA's Generic-Drug Approval Process: Similarities to and Differences From Brand-Name Drugs. Am J Gastroenterol. 2011 Jun;106(6):1018-21
10. D. Thambavita, et, al (2018). Regulatory requirements for the registration of generic medicines and format of drug dossiers: procedures in Sri Lanka in

comparison with selected regulatory authorities. J Pharm Policy Pract. 2018 Jun 21;11:14.

11. Ernst R Berndt, et, al (2018). The generic drug user fee amendments: an economic perspective. J Law Biosci. 2018 Apr 11;5(1):103-141
12. Gandhi Saurabh, et, al (2011). Pharmaceutical Solid Polymorphism in Abbreviated New Drug Application (ANDA) – A Regulatory Perspective.J. Chem. Pharm. Res., 2011, 3(3):6-17
13. Jaime R. Hornecker (2009). Generic Drugs: History, Approval Process, and Current Challenges. U.S. Pharmacist, Published – June 18, 2009
14. JaspreetKaur, et, al (2014). US FDA Drug Approval Strategies for Pharmaceutical Industry, 2014.Int. J. Pharm. Sci. Rev. Res., 25(1), Mar – Apr 2014; Article No. 24, Pages: 137-146
15. Jawahar. N, et, al (2018). Comparison of Generic Drug Application and their Approval Process in US, Europe and Japan.J. Pharm. Sci. & Res. Vol. 10(3), 2018, 523-527
16. Joseph Linsey et al, (2016). COMPARATIVE STUDY FOR GENERIC DRUG APPROVAL PROCESS AND THEIR REGISTRATION AS PER CTD IN EUROPE, USA AND BRAZIL.International Journal of Drug Regulatory Affairs; 2016, 4(2), 1-9
17. MainulHaque, (2019). Generic medicine and prescribing: A quick assessment. Advances in Human Biology ¦ Volume 7 ¦ Issue 3 ¦ September December 2017
18. M. VaseemAkram, et, al (2014). REGULATORY REQUIREMENTS OF DRUG MASTER FILES BY FOOD AND DRUG ADMINISTRATION (USA), EUROPEAN MEDICINES AGENCY (EUROPE) AND HEALTH CANADA (CANADA) AND THEIR COMPARISON. JGTPS / 5(3)-(2014) 2220 - 2224
19. Mulaje SS, et al (2013). PROCEDURE FOR DRUG APPROVAL IN DIFFERENT COUNTRIES: A REVIEW. Journal of Drug Delivery & Therapeutics; 2013, 3(2), 233-238
20. Naziya Rafi, et, al (2018). Regulatory Requirements and Registration Procedure for Generic Drugs in USA.Indian Journal of Pharmaceutical Education and Research | Vol 52 | Issue 4 | Oct-Dec, 2018
21. NithikaKaushal, et, al (2016). Study of regulatory requirements for the conduct of bioequivalence studies in US, Europe, Canada, India, ASEAN and SADC

countries: Impact on generic drug substitution. J App Pharm Sci. 2016; 6(4): 206-222

22. P. Nagaraju, et, al (2015). COMPARISON OF GENERIC DRUG REGISTRATION REQUIREMENTS IN ASEAN COUNTRIES. IJRPC 2015, 5(1), 145-149
23. P. Sindhuja, et, al (2018). COMPARATIVE STUDY OF GENERIC DRUG APPROVAL PROCESS IN EU, USA AND CHINA- A REVIEW.www.wjpps.com Vol 7, Issue 9, 2018, 316-331
24. PuneetDhamija, et, al (2019). Only generics (drugs/names): Is India ready? Indian Journal of Endocrinology and Metabolism / Sep-Oct 2015 / Vol 19 | Issue 5
25. S.M.Shakeel, et, al (2016). COMPARISION OF REGULATORY REQUIREMENTS FOR GENERIC DRUGS DOSSIER SUBMISSION IN UNITED STATES AND CANADA. International Journal of Pharmaceutical Science and Health Care Issue 6, Vol. 6 (November-December 2016)
26. Snehal Shah, et, al (2018). Preliminary requirement for ANDA Filing.International Journal of Drug Regulatory Affairs. 2018; 6(4):1-8
27. S Sravika, et, al (2017). A comprehensive study on regulatory requirements for development and filing of generic drugs globally.The Pharma Innovation Journal 2017; 6(4): 153-158
28. Stephen Barlas (2014). Generic Prices Take Flight- The FDA Is Struggling to Ground Them. P T. 2014 Dec; 39(12): 833,843-845.
29. Stephen Barlas (2017). New User Fee Agreements Aim at Ensuring Relief From High Drug Prices But Trump’s Budget Proposal Threatens to Upend Completed Negotiations. P T. 2017 May; 42(5): 312,314-315,329
30. Suryakanta Swain, et, al (2014). Pharma Regulations for Generic Drug Products in India and US: Case Studies and Future Prospectives. PharmaceutReg Affairs 3:119.
31. SwethaHandoo, et, al (2012). A comprehensive study on regulatory requirements for development and filing of generic drugs globally.Int J Pharm Investig. 2012Jul;2(3):99-105. doi: 10.4103/2230-973X.104392.
32. Useni Reddy Mallu, et al, (2015). API Supplier Change or Addition of Alterate API Supplier in Generic Drug Products: Cost, Quality and Regulatory Factors. Pharm Anal Acta, Volume 6, Issue 5, 1000364